For the functional well-being assessment, all time points were significantly different between treatments ( P < 0.038), except for one time point (at cycle 2, day 28, P = 0.061) which was close to significance.
← all excerpts
Patient-reported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population.
1
—
—